MP-15.17: Comparison of efficacy of post-TURBT adjuvant intravesical mitomycin C therapy in preventing the recurrence of intermediate risk superficial TCC: peri-operative single dose versus delayed multi-dose regimen, short- versus long-term result

Abstract

Superficial bladder TCC especially G.I-II could be effectively managed by initial TUR with adjuvant intravesical therapy using Mitomycin C. To date, there is no worldwide consensus regarding the universally accepted protocol of MMC. Different studies claim better result with conventional delayed multi-dose regimen while others claim superior results with single peri-operative instillation. In the background of controversy we have designed a prospective study in the department of Urology, BSMMU, Dhaka, to compare the efficacy of adjuvant intravesical therapy of MMC, single peri-operative dose versus delayed multi-dose regimen in preventing the recurrence of intermediate risk superficial TCC.